Previous 10 | Next 10 |
home / stock / xphyf / xphyf news
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced two key appointments to continue its focus on research, development an...
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / January 10, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce two key appointments to continue its focus on research, development and commercialization of its biosensor ...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today provided an update on the development of its fast-dissolving CBD oral strips. Wi...
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has completed its acquisition of 3a-diagnostics GmbH (“3a”), first annou...
The acquisition positions XPhyto to be a leading Biosensor producer integrating thin film technology with 3a-diagnostics biosensor technology The acquisition of 3a, a German-based rapid point-of-care diagnostics firm adds IP and a deeply experienced scientific expertise to XPhyto ...
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / December 3, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (the " Company " or " XPhyto ") announces that it has issued an aggregate...
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / November 26, 2021 / XPhyto Therapeutics Corp. (" XPhyto " or the " Company ") (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that further to its news release da...
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) , a bioscience accelerator at the leading-edge of the life science industry, has named a new chief financial officer: Joseph Meagher. A chartered professional accountant (“CPA, CA”) and a chartered director, Meaghe...
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / November 19, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to announce the appointment of Mr. Joseph Meagher as Chief Financial Officer of the Company. Mr. Meagher is a Charter...
News, Short Squeeze, Breakout and More Instantly...
XPhyto Therapeutics Corp Company Name:
XPHYF Stock Symbol:
OTCMKTS Market:
VANCOUVER, BC / ACCESSWIRE / October 3, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT), announces that Per Thoresen and Peter Damouni have resigned as directors of the Company. The Company would like to thank Mr. Thoresen and Mr. Damouni for their c...
VANCOUVER, BC / ACCESSWIRE / September 28, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to announce that, further to its news releases dated August 4 and August 28, 2023, the Company has closed the second tranche of its non-brokered pri...
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / August 4, 2023 / BioNxt Solutions Inc. (" BioNxt " or the " Company ") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce a non-brokered private placement of u...